Berry Consultants has launched Fixed and Adaptive Clinical Trial Simulator (FACTS) 7 for its existing users and new clients.

FACTS 7 consists of new module for platform trial designs.

It will allow users to simulate trials where many treatments are tested, with treatments entering and leaving the trial over time.

The simulation capabilities built in the tool are for continuous and dichotomous endpoints with constraints related to various trial level participants and arms.

Users can specify a maximum time for enrolment, number of subjects, definition of successful treatments, participants per arm and concurrent treatments.

The tool can also simulate treatments arriving at different times at the time of the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also provides allocation options including fixed proportion to control, allocation ratios dependent on the number of treatments and response adaptive randomisation.

Berry Consultants Software Solutions director Tom Parke said: “We are thrilled to be able to take some of the concepts and approaches of platform trials from the Berry Consultants scientific team and be able to apply that to our FACTS software.

“This new module brings some initial capabilities and features to our FACTS users as a first step, and we will be continuing to develop this platform trial software in future releases.

“We will continue to develop FACTS and provide to our users the latest and most innovative features in clinical trial design.”

Through licensing the FACTS software package, the advanced approach of platform trials can be shared to commercial clients with the tool.